February 8, 2024

Genen­tech is tak­ing its spinal mus­cu­lar at­ro­phy aware­ness ef­forts to New York with an orig­i­nal mu­si­cal com­e­dy. The show, called “Most Like­ly Not To…” will

The Eu­ro­pean Med­i­cines Agency ear­li­er this week pro­posed re­duc­ing the reg­u­la­to­ry re­quire­ments for biosim­i­lar de­vel­op­ers due to what it calls “the ad­vances in the an­a­lyt­i­cal

The House Com­mit­tee on Over­sight and Ac­count­abil­i­ty on Tues­day ad­vanced leg­is­la­tion that would ban some com­mon prac­tices of phar­ma­cy ben­e­fit man­agers — the mid­dle­men who

Gilead dis­con­tin­ued its re­main­ing Phase III study of ma­grolimab, an an­ti-CD47 an­ti­body that the com­pa­ny was test­ing for acute myeloid leukemia and its pre­cur­sor dis­ease,

Eli Lil­ly has ex­pressed reser­va­tions about the No­vo-Catal­ent deal and its po­ten­tial im­pact on the wider man­u­fac­tur­ing in­dus­try. “Giv­en the na­ture of this trans­ac­tion —

Gilead is still hunt­ing for deals, par­tic­u­lar­ly in vi­rol­o­gy, on­col­o­gy and in­flam­ma­tion. Dur­ing Tues­day’s fourth-quar­ter earn­ings call, CEO Daniel O’Day said M&A de­ci­sions will be

Plus, news about Pep­Gen and Jasper Ther­a­peu­tics: Jazz Phar­ma­ceu­ti­cals buys Redx Phar­ma’s KRAS in­hibitors: The com­pa­ny is pay­ing Redx $10 mil­lion up­front, with mile­stones up

I-Mab Bio­phar­ma may have long tak­en pride in be­ing a Chi­na-based glob­al play­er, but from here on out, it wants to be known as a

He­paran sul­fate, a po­ten­tial new sur­ro­gate bio­mark­er for neu­rode­gen­er­a­tive dis­eases, is get­ting a lot of love from biotechs this week. De­nali Ther­a­peu­tics on Wednes­day pre­sent­ed

Af­ter strik­ing a bil­lion-dol­lar deal for his last start­up, Asa Abe­liovich has built a new ven­ture with even grander am­bi­tions in treat­ing some of the